DIA Appoints Dr. Haijun Dong as Managing Director for DIA China
Biopharmaceutical executive Dr. Haijun (Lou) Dong has been named as managing director for DIA China.
Biopharmaceutical executive Dr. Haijun (Lou) Dong has been named as managing director for DIA China.
“Dr. Dong brings considerable experience and expertise to DIA, with breadth and depth in the biopharmaceutical industry as well as in academia, and will continue to catalyze DIA’s presence and impact in China,” said DIA Global Chief Executive Barbara L. Kunz.
Dr. Dong previously held executive positions as CEO for Lilly China Research and Development Co., a subsidiary of Eli Lilly and Company, and was president and CEO of IMPACT Therapeutics, Inc. Dr. Dong has been employed by Roche in China and the United States and other Chinese and international companies, serving in R&D, sales and marketing, business development and executive leadership capacities.
Among Dr. Dong’s recent awards and recognition is a full professorship at Nanjing University of Technology. He was named a “Leading Talent in Creativity, Innovation and Entrepreneurship” by the Nanjing New & High Technology Industry Development Zone. He is a frequent speaker for Chinese and international conferences and on university campuses on such topics as China’s strategy for multinational pharmaceutical companies and career and life development choices for college students and young professionals.
Dr. Dong holds an MBA from the China Europe International Business School and a doctorate in chemistry from the University of Washington—building on his undergraduate training as a chemist. He brings considerable experience and expertise in the biopharmaceutical industry and academia to DIA, and will continue to accelerate DIA’s presence and impact in China.
Dr. Dong assumes leadership of DIA China from Dr. Jane Cai upon Dr. Cai’s retirement from the role of DIA China regional director. It is largely due to Dr. Cai’s vision and effort that DIA China was established in 2011 as a legal entity, DIA Beijing Healthcare Information Consulting Ltd. Under Dr. Cai’s leadership, DIA China Annual Meeting participation doubled in attendees and exhibitors, annual educational programs increased exponentially, membership more than doubled, numerous virtual DIA Communities were established, and more technical and educational programs were conducted or will be implemented in 2014 through the DIA China Communities.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
